Results 21 to 30 of about 426,237 (354)

Radiation-induced myeloid leukemia in murine models. [PDF]

, 2014
The use of radiation therapy is a cornerstone of modern cancer treatment. The number of patients that undergo radiation as a part of their therapy regimen is only increasing every year, but this does not come without cost.
Davoren, Michael, Rivina, Leena, Schiestl, Robert H   +2 more
core   +2 more sources

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

Haematologica, 2008
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini, Cristina Mecucci, Giuseppe Saglio, Francesco Lo Coco, Daniela Diverio, Patrick Brown, Fabrizio Pane, Marco Mancini, Maria Paola Martelli, Stefano Pileri, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger   +12 more
doaj   +1 more source

Acute Promyelocytic Leukemia Presenting With a Myeloid Sarcoma of the Spine: A Case Report and Literature Review

Frontiers in Oncology, 2022
Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells. Certain known acute myeloid leukemia cytogenetic abnormalities, in particular t(8,21), has been associated with a higher incidence.
Xuemei Shu, Qiuling Wu, Tao Guo, Hua Yin, Jingdi Liu   +4 more
doaj   +1 more source

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

Haematologica, 2010
Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Jingsong Zhao, Eric D. Hsi, Arie Abo, Wouter Korver   +6 more
doaj   +1 more source

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia [PDF]

, 2018
Quantification of BCR-ABL1 mRNA levels in peripheral blood of chronic myeloidleukemia patients is a strong indicator of response to tyrosine-kinase inhibitors (TKI)treatment.
Bianchini, Michele, Cranco, Santiago, Custidiano, María del Rosario, Foncuberta, Cecilia, Freitas, Josefina, Gutierrez, Leandro German, Koile, Daniel Isaac, Larripa, Irene Beatriz, Moiraghi, Beatriz, Mordoh, Jose, Mosqueira, Celeste, Pavlovsky, Carolina, Pérez, Mariel Ana, Ruiz, María Sol, Sanchez, María Belén, Sánchez Ávalos, Julio César Américo, Ventriglia, Verónica, Yankilevich, Patricio   +17 more
core   +1 more source

The role of peptide and DNA vaccines in myeloid leukemia immunotherapy

Cancer Cell International, 2013
While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable.
Lin Chen, Li Yangqiu
doaj   +1 more source

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

Haematologica, 2012
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, Gautam Borthakur   +10 more
doaj   +1 more source

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

Haematologica, 2012
The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried, Claudia Bodner, Monika M. Pichler, Karin Lind, Christine Beham-Schmid, Franz Quehenberger, Wolfgang R. Sperr, Werner Linkesch, Heinz Sill, Albert Wölfler   +9 more
doaj   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations

Haematologica, 2014
Somatic mutations of TET2, IDH1, and IDH2 have been described in myelodysplastic syndrome. The impact of these mutations on outcome of myelodysplastic syndrome and their progression to secondary acute myeloid leukemia remains unclear.
Tung-Liang Lin, Yasunobu Nagata, Hsiao-Wen Kao, Masashi Sanada, Yusuke Okuno, Chein-Fuang Huang, Der-Cherng Liang, Ming-Chung Kuo, Chang-Liang Lai, En-Hui Lee, Yu-Shu Shih, Hiroko Tanaka, Yuichi Shiraishi, Kenichi Chiba, Tung-Huei Lin, Jin-Hou Wu, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih   +18 more
doaj   +1 more source